|
1
|
Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou
ZX and Chen WQ: Nasopharyngeal carcinoma incidence and mortality in
China in 2010. Chin J Cancer. 33:381–387. 2014.PubMed/NCBI
|
|
2
|
Liu Q, Chen JO, Huang QH and Li YH: Trends
in the survival of patients with nasopharyngeal carcinoma between
1976 and 2005 in Sihui, China: A population-based study. Chin J
Cancer. 32:325–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
International Agency for Research on
Cancer, World Health Organization, . GLOBOCAN 2012: Estimated
cancer incidence, mortality and prevalence worldwide in 2012.
http://globocan.iarc.fr/Default.aspxJuly
1–2015.
|
|
4
|
Sun X, Su S, Chen C, Han F, Zhao C, Xiao
W, Deng X, Huang S, Lin C and Lu T: Long-term outcomes of
intensity-modulated radiotherapy for 868 patients with
nasopharyngeal carcinoma: An analysis of survival and treatment
toxicities. Radiother Oncol. 110:398–403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiao WW, Huang SM, Han F, Wu SX, Lu LX,
Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival,
and late toxicities of locally advanced nasopharyngeal carcinoma
treated by simultaneous modulated accelerated radiotherapy combined
with cisplatin concurrent chemotherapy: Long-term results of a
phase 2 study. Cancer. 117:1874–1883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang R, Cai XY, Yang ZH, Yan Y, Zou X,
Guo L, Sun R, Luo DH, Chen QY, Huang PY, et al: Elevated peripheral
blood lymphocyte-to- monocyte ratio predicts a favorable prognosis
in the patients with metastatic nasopharyngeal carcinoma. Chin J
Cancer. 34:237–246. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meijerman I, Beijnen JH and Schellens JH:
Combined action and regulation of phase II enzymes and multidrug
resistance proteins in multidrug resistance in cancer. Cancer Treat
Rev. 34:505–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li JX, Huang SM, Wen BX and Lu TX:
Prognostic factors on overall survival of newly diagnosed
metastatic nasopharyngeal carcinoma. Asian Pac J Cancer Prev.
15:3169–3173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu J, He ML, Wang L, Chen Y, Liu X, Dong
Q, Chen YC, Peng Y, Yao KT, Kung HF and Li XP: MiR-26a inhibits
cell growth and tumorigenesis of nasopharyngeal carcinoma through
repression of EZH2. Cancer Res. 71:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL,
Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY and Fu L:
MicroRNA-144 promotes cell proliferation, migration and invasion in
nasopharyngeal carcinoma through repression of PTEN.
Carcinogenesis. 34:454–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang
J, McCarthy JB, She X, Zhang W, Ma J, et al: miR-18a promotes
malignant progression by impairing microRNA biogenesis in
nasopharyngeal carcinoma. Carcinogenesis. 34:415–425. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu J, Luo H, Liu X, Peng Y, Zhang B, Wang
L, Xu X, Peng X, Li G, Tian W, et al: miR-9 targets CXCR4 and
functions as a potential tumor suppressor in nasopharyngeal
carcinoma. Carcinogenesis. 35:554–563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma L, Deng X, Wu M, Zhang G and Huang J:
Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and
facilitates invasion of EBV-associated nasopharyngeal carcinoma
cells. FEBS Lett. 588:1562–1570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin W, Wang P, Wang X, Song W, Cui X, Yu H
and Zhu W: Identification of microRNAs and mRNAs associated with
multidrug resistance of human laryngeal cancer hep-2 cells. Braz J
Med Biol Res. 46:546–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong L, Yang Z, Ma J and Fan D: Function
of miRNA in controlling drug resistance of human cancers. Curr Drug
Targets. 14:1118–1127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dai Y, Xie CH, Neis JP, Fan CY, Vural E
and Spring PM: MicroRNA expression profiles of head and neck
squamous cell carcinoma with docetaxel-induced multidrug
resistance. Head Neck. 33:786–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng SC, Liao CT, Peng CH, Cheng AJ, Chen
SJ, Huang CG, Hsieh WP and Yen TC: MicroRNAs MiR-218, MiR-125b and
Let-7g predict prognosis in patients with oral cavity squamous cell
carcinoma. PLoS One. 9:e1024032014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Z, Liu H, Desai S, Schmitt DC, Zhou M,
Khong HT, Klos KS, McClellan S, Fodstad O and Tan M: miR-125b
functions as a key mediator for snail-induced stem cell propagation
and chemoresistance. J Biol Chem. 288:4334–4345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feliciano A, Castellvi J, Artero-Castro A,
Leal JA, Romagosa C, Hernández-Losa J, Peg V, Fabra A, Vidal F,
Kondoh H, et al: miR-125b acts as a tumor suppressor in breast
tumorigenesis via its novel direct targets ENPEP CK2-α, CCNJ, and
MEGF9. PLoS One. 8:e762472013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi
Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the
resistance of breast cancer cells to paclitaxel through suppression
of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J
Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reed JC: Regulation of apoptosis by bcl-2
family proteins and its role in cancer and chemoresistance. Curr
Opin Oncol. 7:541–546. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Teodori E, Dei S, Martelli S, Scapecchi F
and Gualtieri F: The functions and structure of ABC transporters:
Implications for the design of new inhibitors of Pgp and MRP1 to
control multidrug resistance (MDR). Curr Drug Targets. 7:893–909.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Levchenko A, Mehta BM, Niu X, Kang G,
Villafania L, Way D, Polycarpe D, Sadelain M and Larson SM:
Intercellular transfer of P-glycoprotein mediates acquired
multidrug resistance in tumor cells. Proc Natl Acad Sci USA.
102:1933–1938. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng T, Wang J, Chen X and Liu L: Role of
microRNA in anticancer drug resistance. Int J Cancer. 126:2–10.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishida N, Yokobori T, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H and Mori M: MicroRNA
miR-125b is a prognostic marker in human colorectal cancer. Int J
Oncol. 38:1437–1443. 2011.PubMed/NCBI
|
|
26
|
Yuxia M, Zhennan T and Wei Z: Circulating
miR-125b is a novel biomarker for screening non-small-cell lung
cancer and predicts poor prognosis. J Cancer Res Clin Oncol.
138:2045–2050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vriens MR, Weng J, Suh I, Huynh N,
Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E: MicroRNA
expression profiling is a potential diagnostic tool for thyroid
cancer. Cancer. 118:3426–3432. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ferracin M, Bassi C, Pedriali M, Pagotto
S, D'Abundo L, Zagatti B, Corrà F, Musa G, Callegari E, Lupini L,
et al: miR-125b targets erythropoietin and its receptor and their
expression correlates with metastatic potential and ERBB2/HER2
expression. Mol Cancer. 12:1302013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakanishi H, Taccioli C, Palatini J,
Fernandez-Cymering C, Cui R, Kim T, Volinia S and Croce CM: Loss of
miR-125b-1 contributes to head and neck cancer development by
dysregulating TACSTD2 and MAPK pathway. Oncogene. 33:702–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Fu X, Wan Y, Wang Z, Jiang D and
Shi L: miR-125b inhibitor enhance the chemosensitivity of
glioblastoma stem cells to temozolomide by targeting Bak1. Tumor
Biol. 35:6293–6302. 2014. View Article : Google Scholar
|
|
31
|
Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H,
Zhang S, Hong R and Gu X: The role of
miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance
and therapy in human breast cancer. Tumor Biol. 36:7185–7194. 2015.
View Article : Google Scholar
|
|
32
|
Wang HJ, Guo YQ, Tan G, Dong L, Cheng L,
Li KJ, Wang ZY and Luo HF: miR-125b regulates side population in
breast cancer and confers a chemoresistant phenotype. J Cell
Biochem. 114:2248–2257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y
and Chen G: miR-125b confers resistance of ovarian cancer cells to
cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J
Huazhong Univ Sci Technolog Med Sci. 31:543–549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lopez J and Tait SW: Mitochondrial
apoptosis: Killing cancer using the enemy within. Br J Cancer.
112:957–962. 2015. View Article : Google Scholar : PubMed/NCBI
|
